Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7239168 | 0.83 | HDAC8 (0.52) | HDAC8EPHX2MAPK1RIPK1 | |
| SCHEMBL3287288 | 0.82 | EPHX2 (0.70) | HDAC8EPHX2MAPK1 | |
| SCHEMBL21061713 | 0.81 | AHR (0.51) | HDAC8RIPK1GRM7AHR | |
| SCHEMBL21061554 | 0.80 | HDAC8 (0.40) | HDAC8RIPK1GRM7AHRRAB9A | |
| SCHEMBL7246422 | 0.80 | HDAC8 (0.46) | HDAC8EPHX2MAPK1RIPK1RAB9A | |
| SCHEMBL429344 | 0.79 | EPHX2 (0.66) | HDAC8EPHX2MAPK1GRM7 | |
| SCHEMBL22469092 | 0.79 | PNMT (0.40) | HDAC8GRM7 | |
| SCHEMBL11895489 | 0.79 | CA1 (0.50) | HDAC8GRM7RAB9A | |
| SCHEMBL26650239 | 0.79 | CA1 (0.50) | HDAC8GRM7RAB9A | |
| SCHEMBL25330218 | 0.77 | EPHX2 (0.46) | HDAC8EPHX2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2006078697-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | HDAC8 2618/4885EPHX2 1569/4885MAPK1 1461/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | HDAC8 2618/4885EPHX2 1569/4885MAPK1 1461/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | HDAC8 2230/4885EPHX2 753/4885MAPK1 2015/4885 |
| US-20060160850-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | HDAC8 1200/4885EPHX2 531/4885MAPK1 2017/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | HDAC8 2618/4885EPHX2 1569/4885MAPK1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.